### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC,
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC, and MYLAN
PHARMACEUTICALS INC.,
Petitioners

v.

ALMIRALL, LLC, Patent Owner

Case IPR2019-00207<sup>1</sup> Patent 9,517,219

PATENT OWNER'S OPPOSITION TO PETITIONERS' MOTION TO EXCLUDE EVIDENCE

<sup>&</sup>lt;sup>1</sup> Cases IPR2019-00207 and IPR2019-01095 have been joined in this proceeding.



## **TABLE OF CONTENTS**

			Page
INTRODU	CTIO	N	1
ARGUME	NT		5
A	The Board Should Not Exclude the Warner Declaration or Relevant Portions of Dr. Osborne's Declaration		5
	1.	The Warner Declaration Is Not Hearsay	5
	2.	Petitioners Failed to Timely Object to the Warner Declaration	6
	3.	The Warner Declaration Falls Within an Exception to the Rule Against Hearsay	7
	4.	Petitioners' Arguments Go to the Weight, Not Admissibility, of the Warner Declaration	10
	5.	Dr. Osborne's Expert Testimony Regarding the Warner Declaration is Admissible	11
B.	Para	Should the Board Exclude Additional Identified graphs of Expert Declarations Unrelated to the ner Declaration	12
C.	The Board Should Not Exclude Exhibits 2010-2011, 2013, 2017-2018, 2021, 2024, 2026-2027, 2029, 2032, 2038-2040, or 2050-2052		
CONCLUSION			



## **TABLE OF AUTHORITIES**

Page(s	)
CASES	
Actelion Pharms. Ltd. v. Icos Corp., IPR2015-00561, Paper 50 (Aug. 3, 2016)	2
Almirall, LLC v. Amneal Pharms. LLC, C.A. 19-658 (D. Del.)	3
Almirall, LLC v. Taro Pharmaceutical Industries Ltd., C.A. No. 17-cv-663 (D. Del.)	7
Apple Inc. v. Smartflash LLC, CBM2014-00106, Paper 52 (Sept. 25, 2015)14	4
Apple Inc. v. VirnetX Inc., IPR2016-00332, Paper 29 (June 22, 2017)	)
Donnelly Garment Co. v. NLRB, 123 F.2d 215 (8th Cir. 1941)1	1
Funai Elec. Co. v. Gold Charm Ltd., IPR2015-01468, Paper 40 (Dec. 27, 2016)	1
Laird Techs., Inc. v. GrafTech Int'l Holdings, Inc., IPR2014-00025, Paper 45 (Mar. 25, 2015)13	3
Markman v. Westview Instruments, Inc., 52 F.3d 967 (Fed. Cir. 1995)	7
Mexichem Amanco Holdings S.A. v. Honeywell Int'l, Inc., IPR2013-00576, Paper 36 (Sept. 5, 2014)1	1
OddzOn Prods., Inc. v. Just Toys, Inc., 122 F.3d 1396 (Fed. Cir. 1997)13	
Praxair Distribution, Inc. v. Ino Therapeutics LLC, IPR2015-00529, Paper 33 (Dec. 22, 2015)1	



## **TABLE OF AUTORITIES** (Continued)

P	'age(s)
Senmed, Inc. v. Richard-Allan Med. Indus., Inc., 888 F.2d 815 (Fed. Cir. 1989)	7
SK Hynix Inc. v. Netlist, Inc., IPR2017-00562, Paper 36 (July 5, 2018)	.13, 15
SteadyMed Ltd. v. United Therapeutics Corp., IPR2016-00006, Paper 82 (Mar. 31, 2017)	11
STATUTES AND RULES	
Fed. R. Evid. 401	.13, 15
Fed. R. Evid. 402	15
Fed. R. Evid. 702	4, 11
Fed. R. Evid. 703	passim
Fed. R. Evid. 801(d)(2)	6
Fed. R. Evid. 803(8)	7
Fed. R. Evid. 804	.7, 8, 9
Fed. R. Evid. 807	9, 10
OTHER AUTHORITIES	
37 C.F.R. § 1.132	2, 8, 9
37 C.F.R. § 42.64(b)(1)	6
37 C.F.R. § 42.65(a)	12

Patent Owner's Opposition to Petitioners' Motion to Exclude Evidence

### **INTRODUCTION**

The Board should deny Petitioners' motion to exclude what is effectively any evidence (except its own) referencing or concerning the Warner Declaration, including the Warner Declaration itself. To exclude expert testimony because of its reliance on the Warner Declaration would violate not just the letter of, but universal practice under, the Federal Rules of Evidence. The Warner Declaration is not hearsay, as Petitioners argue, but even if it is so considered, it remains admissible into the record on this proceeding under several exceptions. Indeed, Petitioners' request is so misguided that it invites legal error. To exclude as hearsay any part of the public file history, including any § 1.132 declaration therein, on review by the same agency of the very patent that concluded that file history would be arbitrary and capricious. Patent Owner does not cavalierly so suggest as a mere matter of attorney rhetoric—rather, it is with all respect for this Board that Patent Owners submits this would be the result, if not as a general rule, at least on the facts and circumstances and surrounding this proceeding in this posture on the eve of trial.

To exclude a § 1.132 declaration from post-grant proceedings under the AIA—or, as Petitioners soften it, to give it "little or no weight"—under the present circumstances would have arbitrary and thus unjust consequences for disparately-situated patent owners as regards their property rights. The logical extension of



# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

